Related Experiment Video
Updated: May 20, 2026
Quantification of Colonic Stem Cell Mutations
Published on: September 25, 2015
BAY61-3606 affects the viability of colon cancer cells in a genotype-directed manner
Ken S Lau1, Tinghu Zhang, Krystle R Kendall
1Molecular Pathology Unit, Center for Cancer Research, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America.
Background:
K-RAS mutation poses a particularly difficult problem for cancer therapy. Activating mutations in K-RAS are common in cancers of the lung, pancreas, and colon and are associated with poor response to therapy. As such, targeted therapies that abrogate K-RAS-induced oncogenicity would be of tremendous value.
Methods:
We searched for small molecule kinase inhibitors that preferentially affect the growth of colorectal cancer cells expressing mutant K-RAS. The mechanism of action of one inhibitor was explored using chemical and genetic approaches.
Results:
We identified BAY61-3606 as an inhibitor of proliferation in colorectal cancer cells expressing mutant forms of K-RAS, but not in isogenic cells expressing wild-type K-RAS. In addition to its anti-proliferative effects in mutant cells, BAY61-3606 exhibited a distinct biological property in wild-type cells in that it conferred sensitivity to inhibition of RAF. In this context, BAY61-3606 acted by inhibiting MAP4K2 (GCK), which normally activates NFκβ signaling in wild-type cells in response to inhibition of RAF. As a result of MAP4K2 inhibition, wild-type cells became sensitive to AZ-628, a RAF inhibitor, when also treated with BAY61-3606.
Conclusions:
These studies indicate that BAY61-3606 exerts distinct biological activities in different genetic contexts.
Insights
BAY61-3606 inhibits colorectal cancer cell growth with K-RAS mutations. This drug also sensitizes wild-type cells to RAF inhibitors by blocking MAP4K2, offering distinct therapeutic strategies.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Activating mutations in K-RAS are prevalent in lung, pancreas, and colon cancers.
- These mutations are linked to poor therapeutic responses, highlighting the need for targeted therapies.
- Abrogating K-RAS-induced oncogenicity is a critical goal in cancer treatment.
Purpose of the Study:
- To identify small molecule kinase inhibitors targeting colorectal cancer cells with mutant K-RAS.
- To elucidate the mechanism of action of a novel inhibitor, BAY61-3606.
Main Methods:
- Screening for small molecule kinase inhibitors.
- Evaluating inhibitor effects on colorectal cancer cell proliferation (mutant vs. wild-type K-RAS).
- Employing chemical and genetic approaches to determine the mechanism of action.
Main Results:
- BAY61-3606 selectively inhibited proliferation in colorectal cancer cells with mutant K-RAS.
- BAY61-3606 conferred sensitivity to RAF inhibition in wild-type cells.
- The drug's mechanism involved inhibiting MAP4K2 (GCK), which modulates NFκβ signaling.
Conclusions:
- BAY61-3606 demonstrates context-dependent biological activities.
- The findings suggest distinct therapeutic applications for BAY61-3606 based on K-RAS mutational status.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:16In-vitro Mutagenesis
01:25Mutagenicity and Carcinogenicity
01:16In vitro Mutagenesis
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...